Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Feb 2021
Historique:
pubmed: 1 7 2020
medline: 26 10 2021
entrez: 29 6 2020
Statut: ppublish

Résumé

The role of the A>G polymorphism at position 19911 in the prothrombin gene (factor [F] 2 at rs3136516) as a risk factor for venous thromboembolism [VTE] is still unclear. To evaluate the presence of the F2 polymorphism in VTE patients compared to healthy blood donors and to adjust the results for common inherited thrombophilias [IT], age at onset and blood group [BG], and to calculate the risk of VTE recurrence. We investigated 1012 Caucasian patients with a diagnosis of VTE for the presence of the F2 rs3136516 polymorphism and compared these with 902 healthy blood donors. Odds ratios [OR] together with their 95% confidence intervals were calculated adjusted for F5 at rs6025, F2 at rs1799963, blood group, age and gender. In addition, we evaluated the risk of recurrent VTE during patient follow-up calculating hazard ratios [HR] together with their 95% CI. Compared with the AA wildtype, the F2 GG and AG genotypes (rs3136516) were associated with VTE (OR 1.48 and 1.45). The OR in F5 carriers compared to controls was 5.68 and 2.38 in patients with F2 (rs1799963). BG "non-O" was significantly more often diagnosed in patients compared to BG "O" (OR 2.74). VTE recurrence more often occurred in males (HR 2.3) and in carriers with combined thrombophilia (HR 2.11). Noteworthy, the rs3136516 polymorphism alone was not associated significantly with recurrence. In Caucasian patients with VTE the F2 GG/GA genotypes (rs3136516) were moderate risk factors for VTE. Recurrence was associated with male gender and combined thrombophilia.

Identifiants

pubmed: 32594420
doi: 10.1007/s11239-020-02169-6
pii: 10.1007/s11239-020-02169-6
pmc: PMC7886710
doi:

Substances chimiques

Blood Group Antigens 0
Prothrombin 9001-26-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-501

Subventions

Organisme : Interdisziplinäres Zentrum für Klinische Forschung
ID : IZKF: CRA01-09
Organisme : Gesellschaft für Thrombose und Hämostaseforschung/ Society of Thrombosis and Hemostasis Research" (GTH)
ID : GTH 2016

Commentaires et corrections

Type : ErratumIn

Références

Transl Res. 2015 May;165(5):537-48
pubmed: 25639953
Nature. 1994 May 5;369(6475):64-7
pubmed: 8164741
Lancet. 2006 Jul 29;368(9533):371-8
pubmed: 16876665
Blood. 2019 Nov 7;134(19):1645-1657
pubmed: 31420334
Thromb Haemost. 2001 Jun;85(6):1066-70
pubmed: 11434686
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1992-7
pubmed: 15976329
Chest. 2012 Feb;141(2 Suppl):e737S-e801S
pubmed: 22315277
J Thromb Haemost. 2006 Dec;4(12):2587-92
pubmed: 17059428
Arch Intern Med. 1991 May;151(5):933-8
pubmed: 2025141
Blood. 1996 Nov 15;88(10):3698-703
pubmed: 8916933
Am J Hematol. 2012 May;87 Suppl 1:S63-7
pubmed: 22367958
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Haematologica. 2019 Aug;104(8):1676-1681
pubmed: 30679327
Lancet. 1999 Apr 3;353(9159):1167-73
pubmed: 10209995
Blood Cells Mol Dis. 2017 Sep;67:2-13
pubmed: 28017497
Ann Neurol. 2009 Dec;66(6):754-8
pubmed: 20033984
Thromb Haemost. 2001 Jul;86(1):395-403
pubmed: 11487029
Blood. 2000 May 1;95(9):2780-5
pubmed: 10779421
BMJ. 2011 Feb 24;342:d813
pubmed: 21349898
Balkan J Med Genet. 2015 Apr 10;17(2):43-8
pubmed: 25937797
Blood. 2012 Aug 16;120(7):1510-5
pubmed: 22581447
J Thromb Haemost. 2006 Dec;4(12):2582-6
pubmed: 16981886
Thromb Haemost. 2014 Dec;112(6):1103-9
pubmed: 25187297
J Thromb Haemost. 2019 Jul;17(7):1144-1152
pubmed: 31033194
Lancet. 2000 May 6;355(9215):1627-32
pubmed: 10821379
Br J Haematol. 2002 Aug;118(2):610-4
pubmed: 12139755

Auteurs

Verena Limperger (V)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany. verena.limperger@gmail.com.

Gili Kenet (G)

National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Centre, Tel-Hashomer, Israel.
The Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Tel Aviv, Israel.

Bettina Kiesau (B)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Max Köther (M)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Malin Schmeiser (M)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Florian Langer (F)

Department of Hematology & Oncology, Univ. Hospital Hamburg, Hamburg, Germany.

David Juhl (D)

Institute of Transfusion Medicine, Univ. Hospital Kiel & Lübeck, Lübeck, Germany.

Maria Shneyder (M)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Andre Franke (A)

Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.

Ulrich K Klostermeier (UK)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Rolf Mesters (R)

Department of Medicine/ Hematology & Oncology, Univ. Hospital Münster, Münster, Germany.

Frank Rühle (F)

Institute of Human Genetics, Westfälische-Wilhelms-University, Münster, Germany.

Monika Stoll (M)

Institute of Human Genetics, Westfälische-Wilhelms-University, Münster, Germany.
Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.

Dagmar Steppat (D)

Institute of Transfusion Medicine, Univ. Hospital Kiel & Lübeck, Lübeck, Germany.

Dorothee Kowalski (D)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Angela Rocke (A)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Piotr Kuta (P)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Tido Bajorat (T)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Antje Torge (A)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Bruno Neuner (B)

Department of Anesthesiology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Berlin, Germany.

Ralf Junker (R)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany.

Ulrike Nowak-Göttl (U)

UKSH, Institute of Clinical Chemistry, Hemostasis Unit, Arnold-Heller-Str. 3 Building 17, Kiel, 24105, Germany. leagottl@uksh.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH